

					
						November 12, 2017 - By Linda Rogers
Among 7 analysts covering VEREIT Inc (NYSE:VER), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. VEREIT Inc had 7 analyst reports since September 1, 2015 according to SRatingsIntel. Mizuho initiated the stock with “Neutral” rating in Friday, October 14 report. The stock has “Overweight” rating by Capital One on Friday, August 5. The company was upgraded on Friday, November 6 by JP Morgan. The firm has “Mkt Outperform” rating given on Monday, January 9 by JMP Securities. DA Davidson initiated the shares of VER in report on Thursday, September 17 with “Neutral” rating. The rating was downgraded by CapitalOne to “Equal Weight” on Monday, December 21. Goldman Sachs initiated the stock with “Buy” rating in Tuesday, September 1 report. See Vereit Inc (NYSE:VER) latest ratings:The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) hit a new 52-week low and has $33.89 target or 4.00% below today’s $35.30 share price. The 9 months bearish chart indicates high risk for the $85.24 billion company. The 1-year low was reported on Nov, 12 by Barchart.com. If the $33.89 price target is reached, the company will be worth $3.41B less. The stock decreased 1.33% or $0.48 on November 10, reaching $35.3. About 5.96 million shares traded or 2.41% up from the average. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 12, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.GlaxoSmithKline plc is a global healthcare company. The company has market cap of $85.24 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 28.17 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was upgraded by BNP Paribas to “Neutral” on Wednesday, April 5. On Tuesday, October 20 the stock rating was upgraded by Credit Suisse to “Neutral”. As per Wednesday, September 14, the company rating was downgraded by BNP Paribas. The company was upgraded on Wednesday, December 9 by Bank of America. Jefferies upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Thursday, July 14 to “Buy” rating. As per Wednesday, April 26, the company rating was maintained by JP Morgan. The firm has “Buy” rating by Investec given on Thursday, October 20. The rating was upgraded by BNP Paribas to “Neutral” on Tuesday, September 15. Bryan Garnier & Cie upgraded the stock to “Buy” rating in Wednesday, January 27 report. The company was downgraded on Thursday, October 26 by Bank of America. - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.By Linda Rogers